PROGRESS-AD Efficacy and safety of GSK4527226 in participants with early Alzheimer's disease Sponsor GlaxoSmithKline Clinical Trial Phase II Status Ongoing studies but not recruiting Drug GSK4527226
AB21004 Masitinib in patients with mild to moderate Alzheimer's disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor AB Science Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Masitinib
ACP-204-006 ACP-204 in adults with Alzheimer's disease psychosis Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor ACADIA Pharmaceuticals Clinical Trial Phase III Status Currently recruiting Drug ACP-204
ADAGIO 2 A phase 3 study to evaluate the safety and efficacy of KarXT + KarX-EC for the treatment of agitation associated with Alzheimer's disease Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Bristol-Myers Squibb Clinical Trial Phase III Status Currently recruiting Drug KarXT + KarX-EC
ADEPT-3 Open-label extension study to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's disease Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Bristol Myers Squibb Clinical Trial Phase III Status Enrolling by invitation Drug KarXT (combines xanomeline with trospium chloride)
ADEPT-4 A study to evaluate KarXT as a treatment for psychosis associated with Alzheimer's disease Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Bristol Myers Squibb Clinical Trial Phase III Status Currently recruiting Drug KarXT (combines xanomeline with trospium chloride)
Brochures: AD and Related Diseases- Symptoms Evolution Diagnosis Treatments Brochure Target Audience People with Dementia Informal Carers Communities BAME/BME Available languages English Initiative Type Printed Materials
By your side fighting dementia Brochure Target Audience People with Dementia Informal Carers Communities BAME/BME Available languages English Initiative Type Printed Materials
CAFCA Effect of caffeine on cognition in Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor University Hospital, Lille Clinical Trial Phase III Status Currently recruiting Drug Caffeine
CELIA A randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Biogen Clinical Trial Phase II Status Ongoing studies but not recruiting Drug BIIB080
CHOLINE-2 Donepezil versus non-drug treatment in Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Assistance Publique - Hôpitaux de Paris Clinical Trial Phase III Status Currently recruiting Drug Donepezil
Clarity AD A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Eisai Clinical Trial Phase III Status Ongoing studies but not recruiting Drug BAN2401
DNLI-H-0001 A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL593 in healthy participants and participants with Frontotemporal Dementia (FTD-GRN) Sponsor Denali Therapeutics Inc. Clinical Trial Phase II Status Ongoing studies but not recruiting Drug DNL593
GABRIELLA A clinical trial to look at how well RO7269162 works in people who are at risk of Alzheimer’s disease or who have mild cognitive impairment due to Alzheimer’s disease and how safe RO7269162 is at different doses At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Hoffmann-La Roche Clinical Trial Phase II Status Ongoing studies but not recruiting Drug RO7269162
GSK4527226 Open-label extension study in participants with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor GlaxoSmithKline Clinical Trial Phase II Status Enrolling by invitation Drug GSK4527226
IL-2-AD Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Centre Hospitalier St Anne Clinical Trial Phase II Status Currently recruiting Drug IL-2 (PROLEUKIN ®)
MINDSET 2 A study to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor Bristol-Myers Squibb Clinical Trial Phase III Status Currently recruiting Drug KarXT + KarX-EC
Neflamapimod An open-label Phase 2a clinical study of the P38 alpha kinase inhibitor neflamapimod in patients with dementia with Lewy Bodies Dementia with Lewy Bodies Sponsor Eip Pharma Clinical Trial Phase II Status Ongoing studies but not recruiting Drug Neflamapimod
POLARIS-AD Phase 3, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of AR1001 in participants with early Alzheimer's disease Sponsor AriBio Co Clinical Trial Phase III Status Ongoing studies but not recruiting Drug AR1001
Preventing carer exhaustion Brochure Target Audience People with Dementia Informal Carers Communities BAME/BME Available languages English Initiative Type Printed Materials
PROCLAIM Phase 1/2 clinical trial of LY3884963 in patients with frontotemporal dementia with progranulin mutations Frontotemporal dementia Sponsor Prevail Therapeutics Clinical Trial Phase II Status Ongoing studies but not recruiting Drug LY3884963
Reτain A Study of JNJ-64042056 in participants with preclinical Alzheimer's disease At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Sponsor Janssen Pharmaceutica N.V., Belgium Clinical Trial Phase II Status Ongoing studies but not recruiting Drug JNJ-64042056
TRONTIER 1 A clinical trial of trontinemab in participants with early symptomatic Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor F. Hoffmann- La Roche Clinical Trial Phase III Status Currently recruiting Drug Trontinemab
TRONTIER 2 A clinical trial of trontinemab in participants with early symptomatic Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor F. Hoffmann- La Roche Clinical Trial Phase III Status Currently recruiting Drug Trontinemab
VHB937 A clinical trial to learn about the effects of VHB937 in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Novartis Pharmaceuticals Clinical Trial Phase II Status Currently recruiting Drug VHB937
VISTA A study to assess the efficacy and safety of ML-007C-MA for the treatment of Alzheimer's disease psychosis Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor MapLight Therapeutics Clinical Trial Phase II Status Currently recruiting Drug ML-007C-MA
